If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 1 - 10 of 23
Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
Objective
This study will evaluate the efficacy and safety of multiple therapies that are selected
using somatic alterations and potential predictive biomarkers identified via NGS assays
in patients with solid tumors.
using somatic alterations and potential predictive biomarkers identified via NGS assays
in patients with solid tumors.
Protocol No
HOFFMANN-BO41932-TAPISTRY
A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
Objective
Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary HNSCC
Protocol No
ECOG-EA3191
Categories
An Open-Label, Navigational Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy for Patients with Aggressive Malignancies and Poor Prognoses
Objective
IIT-GEORGE-I-PREDICT
Protocol No
IIT-GEORGE-I-PREDICT
Categories
Cancer,
Colorectal,
Gynecologic Cancers,
Esophagus,
Other Urologic,
Head and Neck Cancers,
Early Phase/Multiple Disease Site Cancers,
Esophagus,
Skin Cancers,
Stomach,
Prostate and Urologic Cancers,
Pancreas/Liver,
Breast Cancers,
Other Gastrointestinal,
Sarcoma,
Gastrointestinal Cancers,
Lung,
Thoracic Cancers
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors
Objective
A Dose-Escalation Study of XL092 in Subjects with Unresectable Advanced or Metastatic Solid Tumors
Protocol No
EXELIXIS-XL092-002
A Multicenter, Randomized, Open-Label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab Relative to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients with Cancer Associated VTE
Objective
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE (ASTER)
Protocol No
ANTHOS-ANT-007
Categories
Cancer,
Eye/Orbital Cancers,
Skin Cancers,
Cervix,
Lip, Oral Cavity and Pharynx,
Sarcoma,
Other Gastrointestinal,
Other Blood Related,
Pancreas/Liver,
Uterine,
Other Respiratory,
Gynecologic Cancers,
Brain and Spine Cancers,
Bladder,
Lung,
Head and Neck Cancers,
Leukemia,
Prostate,
Esophagus,
Thoracic Cancers,
Colorectal,
Hematologic/Blood Related Cancers,
Gastrointestinal Cancers,
Kidney,
Endocrine Cancers,
Prostate and Urologic Cancers,
Multiple Myeloma,
Breast Cancers
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
Objective
Collection of research data and samples from patients who experience immunotherapy side effects
Protocol No
ALLIANCE-A151804
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ficlatuzumab in Combination with Cetuximab in Participants with Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma (FIERCE-HN)
Objective
Ficlatuzumab in Combination with Cetuximab in Participants with Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma (FIERCE-HN)
Protocol No
AVEO-AV-299-23-301
Categories
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion
Objective
A Phase 1/2 Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion
Protocol No
MIRATI-1719-001
Categories
Cancer,
Other Skin,
Thoracic Cancers,
Gynecologic Cancers,
Other Gastrointestinal,
Early Phase/Multiple Disease Site Cancers,
Lip, Oral Cavity and Pharynx,
Melanoma, Skin,
Esophagus,
Bladder,
Pancreas/Liver,
Prostate,
Skin Cancers,
Kidney,
Prostate and Urologic Cancers,
Head and Neck Cancers,
Colorectal,
Gastrointestinal Cancers,
Sarcoma,
Breast Cancers
Inhibition of Oral Tumorigenesis by Antitumor B
Objective
IIT-WONG-ATB-RANDOMIZED
Protocol No
IIT-WONG-ATB-RANDOMIZED
Categories
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Subjects with KRAS G12C Mutant Advanced Solid Tumors
Objective
This project is being done to test the safety and tolerability of MK-1084 alone in combination with pembrolizumab in patients with solid tumor cancers that have a mutated KRAS gene.
Protocol No
MERCK-MK1084-001
Categories
Cancer,
Kidney,
Other Skin,
Thoracic Cancers,
Sarcoma,
Gastrointestinal Cancers,
Cervix,
Prostate and Urologic Cancers,
Other Gynecologic,
Breast Cancers,
Ovary,
Gynecologic Cancers,
Head and Neck Cancers,
Early Phase/Multiple Disease Site Cancers,
Endocrine Cancers,
Melanoma, Skin,
Eye/Orbital Cancers,
Skin Cancers